Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 17/20 | 0.50 |
| ▸ | CCNB1 | P14635 | 17/20 | 0.50 |
| ▸ | AURKA | O14965 | 15/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CDK4 | P11802 | 4/20 | 0.43 |
| ▸ | CCND1 | P24385 | 4/20 | 0.43 |
| ▸ | CCND2 | P30279 | 4/20 | 0.43 |
| ▸ | CCND3 | P30281 | 4/20 | 0.43 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.43 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.43 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.43 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.43 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.43 |
| ▸ | CDK2 | P24941 | 2/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3591794 | 0.94 | CDK1 (0.48) | CDK1CCNB1AURKACYP3A4CYP2C9 | |
| SCHEMBL3586575 | 0.91 | CDK1 (0.52) | CDK1CCNB1AURKACYP3A4CYP2C9 | |
| SCHEMBL3575825 | 0.89 | AURKA (0.53) | CDK1CCNB1AURKACYP3A4CYP2C9 | |
| SCHEMBL3582161 | 0.88 | AURKA (0.55) | CDK1CCNB1AURKACYP3A4CYP2C9 | |
| SCHEMBL3591861 | 0.85 | AURKA (0.54) | CDK1CCNB1AURKACYP3A4CYP2C9 | |
| SCHEMBL1356054 | 0.82 | CDK4 (0.47) | CDK1CCNB1AURKACYP3A4CYP2C9 | |
| SCHEMBL3587878 | 0.80 | AURKA (0.57) | CDK1CCNB1AURKACYP3A4CYP2C9 | |
| SCHEMBL3862278 | 0.77 | AURKA (0.48) | CDK1CCNB1AURKACYP3A4CYP2C9 | |
| SCHEMBL1353819 | 0.77 | CDK1 (0.81) | CDK1CCNB1AURKACYP3A4CYP2C9 | |
| SCHEMBL1353780 | 0.76 | EIF2AK4 (0.60) | CDK1CCNB1AURKACYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190787-A1 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC | 2010-07-29 | — | — | US | claimed |
| EP-2108019-A2 | 1-H-PYRAZOLO[3,4B]PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES | Biogen Idec MA, Inc. (US) | 2009-10-14 | — | — | EP | claimed |
| WO-2008094575-A2 | 1-H-PYRAZOLO(3,4B)PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES | BIOGEN IDEC MA INC. (US) | 2008-08-07 | — | — | WO | claimed |
| US-20100190787-A1 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC | 2010-07-29 | — | — | US | disclosed |
| EP-2108019-A2 | 1-H-PYRAZOLO[3,4B]PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES | Biogen Idec MA, Inc. (US) | 2009-10-14 | — | — | EP | disclosed |
| WO-2008094575-A2 | 1-H-PYRAZOLO(3,4B)PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES | BIOGEN IDEC MA INC. (US) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190787-A1 | Modulators of Mitotic Kinases | CDK1, BUB1, BUB1B | CDK1 1/4885CCNB1 17/4885AURKA 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.